Prevalence, awareness, and burden of major depressive disorder in urban China.

Abstract:

OBJECTIVES:This cross-sectional study examined the prevalence and burden of major depressive disorder (MDD) among adults in urban China. METHODS:Data were included from the 2012 China National Health and Wellness Survey. Respondents self-reporting physician diagnosis of depression and screening positive for MDD (Patient Health Questionnaire-9), plus those screening positive for MDD, but undiagnosed and not experiencing depression, were compared with non-depressed controls. Outcomes included health-related quality of life (HRQoL), productivity loss, and resource utilization. Multivariable models assessed outcomes as a function of MDD, controlling for covariates. RESULTS:MDD prevalence was 6.0%; only 8.3% of these respondents were diagnosed, among whom 51.5% currently used prescription medication for depression. Adults with MDD (diagnosed or undiagnosed) reported significantly poorer HRQoL and greater productivity loss and resource utilization than controls. CONCLUSIONS:MDD in urban China may be under-diagnosed and undertreated. Awareness and better access to treatments may help alleviate the burden of MDD.

authors

Gupta S,Goren A,Dong P,Liu D

doi

10.1586/14737167.2016.1102062

subject

Has Abstract

pub_date

2016-06-01 00:00:00

pages

393-407

issue

3

eissn

1473-7167

issn

1744-8379

journal_volume

16

pub_type

杂志文章
  • Global cost modeling analysis of HIV-1 and HCV viral load assays.

    abstract::This review addresses hidden costs associated with the Bayer VERSANT assay, Roche AMPLICOR MONITOR test and COBAS AMPLICOR MONITOR test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effectiv...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.4.383

    authors: Elbeik T,Chen YM,Soutchkov SV,Loftus RA,Beringer S

    更新日期:2003-08-01 00:00:00

  • The process of reconciliation: evaluation of guidelines for translating quality-of-life questionnaires.

    abstract::Reconciliation refers to the process through which two or more independent forward translations are merged into one single translation. This critical step in the translation process is difficult to formalize. The purpose of this review is to analyze how reconciliation is specified in leading guidelines for the transla...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.102

    authors: Koller M,Kantzer V,Mear I,Zarzar K,Martin M,Greimel E,Bottomley A,Arnott M,Kuliś D,ISOQOL TCA-SIG.

    更新日期:2012-04-01 00:00:00

  • Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.

    abstract:INTRODUCTION:In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1277144

    authors: Kwon SH,Park SK,Byun JH,Lee EK

    更新日期:2017-08-01 00:00:00

  • Economic considerations and future directions for lung volume reduction surgery.

    abstract::Chronic obstructive pulmonary disease is a major cause of morbidity and mortality throughout the world. Standard management includes avoidance of causative factors such as smoking, and pharmacological therapy with combinations of inhaled and/or oral bronchodilators and corticosteroids. Lung transplantation is an estab...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.6.729

    authors: Reed A,Williams T,Snell G

    更新日期:2003-12-01 00:00:00

  • Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain.

    abstract:AIM:Limitations of vitamin K antagonists (VKAs) include frequent monitoring, dietary restrictions and drug interactions. This study conducted an indepth exploration of perspectives of VKA therapy in respondents with atrial fibrillation or venous thromboembolism. METHODS:A total of 60 respondents, recruited from the UK...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.48

    authors: Wild D,Murray M,Donatti C

    更新日期:2009-10-01 00:00:00

  • The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.

    abstract::The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference was on reimbursement decisions for medicines using health technology assessment ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1080/14737167.2017.1385394

    authors: Novakovic T,Martin AP,Parker M,Ferrario A,Vukovic S,Łanda K,Duba J,Dankó D,Kotsopoulos N,Godman B,Ristic J,Stefanovic D,Tesic D

    更新日期:2017-12-01 00:00:00

  • Persistence with medication and overactive bladder: an ongoing challenge.

    abstract:INTRODUCTION:For optimum results from pharmacological management of overactive bladder, adherence to prescribed medication is required. Overactive bladder treatment has been compromised by low adherence and persistence to medications, losing many people who might benefit from treatment and exposing them to unnecessary ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2016.1203258

    authors: Wagg A

    更新日期:2016-08-01 00:00:00

  • Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer.

    abstract:INTRODUCTION:Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a m...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2019.1536549

    authors: Petrou P

    更新日期:2019-04-01 00:00:00

  • Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).

    abstract:INTRODUCTION:During the past few years, medical-economic evaluation of lung cancers (LCs) has become unavoidable. Total management costs have been rising constantly, with values almost doubling every 10 years. The financial impact will be even greater with the new molecules now marketed. The methodology for these studi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2018.1485099

    authors: Vergnenègre A,Chouaïd C

    更新日期:2018-10-01 00:00:00

  • Priority setting in healthcare: towards guidelines for the program budgeting and marginal analysis framework.

    abstract::Economists' approaches to priority setting focus on the principles of opportunity cost, marginal analysis and choice under scarcity. These approaches are based on the premise that it is possible to design a rational priority setting system that will produce legitimate changes in resource allocation. However, beyond is...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.66

    authors: Peacock SJ,Mitton C,Ruta D,Donaldson C,Bate A,Hedden L

    更新日期:2010-10-01 00:00:00

  • Correlates and economic outcomes of proton pump inhibitor use by routes in intensive care unit patients.

    abstract::Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a P...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2014.940902

    authors: Sankaranarayanan J,Reardon T,Olsen KM

    更新日期:2014-10-01 00:00:00

  • Antibiotics and reduced risk of COPD re-exacerbations.

    abstract::Chronic obstructive pulmonary disease is a progressive disease of the airways in which respiratory symptoms aggravate transitorily during disease exacerbations. The treatment of the disease in its stable state is the most important factor in reducing related morbidity, but exacerbation therapy might also impact on sub...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.33

    authors: Antoniu SA

    更新日期:2009-08-01 00:00:00

  • Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries.

    abstract:INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2019.1554437

    authors: Inotai A,Ágh T,Karpenko AW,Zemplényi A,Kaló Z

    更新日期:2019-04-01 00:00:00

  • Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan.

    abstract:OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1800457

    authors: Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

    更新日期:2020-08-01 00:00:00

  • Cost-effective approaches to influenza prevention and treatment.

    abstract::Influenza, the seventh leading cause of death in the USA, accounts for 35,000 deaths and over 200,000 hospitalizations annually in that country alone. Recent advances in influenza vaccines, diagnosis and treatment have created numerous options for practicing clinicians, as well as economic opportunities for the makers...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.2.141

    authors: Rothberg M

    更新日期:2005-04-01 00:00:00

  • Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma.

    abstract:OBJECTIVES:We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. STUDY DE...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2015.978292

    authors: Cangelosi MJ,Ortendahl JD,Meckley LM,Bentley TG,Anene AM,Shriner KM,Fox J

    更新日期:2015-04-01 00:00:00

  • Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.

    abstract:BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1476142

    authors: Grewal S,Ramsey S,Balu S,Carlson JJ

    更新日期:2018-08-01 00:00:00

  • Assessing the equality of means of healthcare costs.

    abstract::The main analytic problems for assessing the equality of means of healthcare costs are the skewed and heteroscedastic nature of the distribution of healthcare costs and the occurrence of persons with zero cost values. Without taking these special features into consideration, any statistical method may lead to the wron...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.5.561

    authors: Zhou XH,Ramsey S

    更新日期:2003-10-01 00:00:00

  • Corneal transplantation using the Descemet's stripping endothelial keratoplasty technique.

    abstract::Descemet's stripping endothelial keratoplasty (DSEK) is a relatively new technique that is rapidly replacing full-thickness procedures for those patients needing corneal transplantation for endothelial dysfunction. Benefits of DSEK include a faster recovery, reduced astigmatism, fewer postoperative complications and r...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.2.137

    authors: Kharod BV,Carlson AN

    更新日期:2007-04-01 00:00:00

  • Radiotherapy cost-calculation and its impact on capacity planning.

    abstract::The rapid rise in health care expenses has resulted in an increased interest in the cost of treatments from a cost-effectiveness point of view for management purposes and in a reimbursement setting. The economics of radiotherapy within the global context of health care, and more specifically of cancer therapy, are dis...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.4.497

    authors: Lievens Y,Slotman BJ

    更新日期:2003-08-01 00:00:00

  • Future of healthcare reform in the USA: lessons from abroad.

    abstract::Healthcare reform in any nation is an evolving process. Brought about by demographic, technological, social, cultural, economic and political factors, all healthcare systems are continually confronting issues related to cost, access and quality. This paper examines other countries' approaches to healthcare in the ongo...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2.3.279

    authors: O'Rourke TW,Iammarino NK

    更新日期:2002-06-01 00:00:00

  • How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.

    abstract::In recent years, the quest for more comprehensiveness, structure and transparency in reimbursement decision-making in healthcare has prompted the research into alternative decision-making frameworks. In this environment, multi-criteria decision analysis (MCDA) is arising as a valuable tool to support healthcare decisi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.859525

    authors: Diaby V,Goeree R

    更新日期:2014-02-01 00:00:00

  • Non-communicating children's pain checklist: better pain assessment for severely disabled children.

    abstract::Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.3.327

    authors: Breau LM

    更新日期:2003-06-01 00:00:00

  • Modeling cost-effectiveness of pharmaceuticals in Alzheimer's disease.

    abstract::Alzheimer's disease is a neurodegenerative disorder characterized by cognitive and behavioral deficits. Donepezil and memantine are two medications used to treat the symptoms of cognitive decline in Alzheimer's disease. A modeled cost-effectiveness analysis found that treatment with donepezil to be less costly and mor...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/erp.12.21

    authors: Oremus M,Tarride JE

    更新日期:2012-06-01 00:00:00

  • The German method for setting ceiling prices for drugs: in some cases less data are required.

    abstract::The Institute for Quality and Efficiency in Health Care in Germany makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effects in each therapeutic area. The analysis requires, when applicable, calculation of savings from avoided clinical events and increased f...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.11.45

    authors: Gandjour A,Gafni A

    更新日期:2011-08-01 00:00:00

  • Patient-reported outcomes measurements in epilepsy.

    abstract::This review was designed to explore and review the range of patient-reported outcomes used to assess people with epilepsy. Literature searches were conducted through EMBASE.com and supplemented with hand searching of relevant articles. References obtained through hand searches were compared with EMBASE.com citations u...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.4.373

    authors: Stafford M,Gavriel S,Lloyd A

    更新日期:2007-08-01 00:00:00

  • The START study: when to start to treat with inhaled steroids in asthma?

    abstract::Asthma is an inflammatory disorder with increasing prevalence and significant morbidity worldwide. Inhaled steroids improve asthma symptoms, reduce exacerbations number and severity, and the need for oral steroids. Due to their potent anti-inflammatory effect, inhaled steroids represent the most effective maintenance ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/14737167.3.3.223

    authors: Antoniu SA

    更新日期:2003-06-01 00:00:00

  • Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model.

    abstract:OBJECTIVE:To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. METHODS:A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2015.1065734

    authors: Hu S,Yu X,Chen S,Clay E,Toumi M,Milea D

    更新日期:2015-01-01 00:00:00

  • Threshold denial rates in prior authorization prescription programs.

    abstract::In this special report, the economics of prior authorization is examined with a focus on the break-even rate that requests are denied. Using a simple theoretical model, comparative static results are derived and used to consider the cost-effectiveness implications of future changes in prior authorization policies. ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.2.165

    authors: Grant WC,Yoder DM,Mullins CD

    更新日期:2004-04-01 00:00:00

  • Effectiveness of non-pharmacological COPD management on health-related quality of life - a systematic review.

    abstract::Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide. The chronic progressive disease is accompanied by a high loss of health-related quality of life (HRQoL). The available drugs usually only have symptomatic effects; therefore, non-pharmacological therapies are ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1734455

    authors: Hindelang M,Kirsch F,Leidl R

    更新日期:2020-02-01 00:00:00